$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000112623417000081 Filed on August 03, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$5.482M	$10.37M	$2.012M
YoY Change	-64.28%	415.41%	-72.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.900M	$8.900M	$8.600M
YoY Change	2.6%	3.49%	17.81%
% of Gross Profit
Research & Development	$18.48M	$18.20M	$27.41M
YoY Change	-24.46%	-33.6%	69.93%
% of Gross Profit
Depreciation & Amortization	$400.0K	$300.0K	$600.0K
YoY Change	33.33%	-50.0%	100.0%
% of Gross Profit
Operating Expenses	$26.39M	$27.10M	$36.54M
YoY Change	-18.08%	-25.84%	56.24%
Operating Profit	-$20.91M	-$16.73M	-$34.53M
YoY Change	25.28%	-51.56%	116.59%
Interest Expense	$3.000K	$7.000K	$6.000K
YoY Change	-40.0%	16.67%	50.0%
% of Operating Profit
Other Income/Expense, Net	$160.0K	$1.000K	$60.00K
YoY Change	742.11%	-98.33%	172.73%
Pretax Income	-$20.75M	-$16.73M	-$34.47M
YoY Change	23.13%	-51.47%	116.51%
Income Tax	-$119.0K	$0.00	-$2.100M
% Of Pretax Income
Net Earnings	-$20.63M	-$16.73M	-$32.39M
YoY Change	32.73%	-48.36%	129.86%
Net Earnings / Revenue	-376.25%	-161.29%	-1609.79%
Basic Earnings Per Share	-$0.69	-$0.57	-$1.12
Diluted Earnings Per Share	-$6.242M	-$5.219M	-$1.12
COMMON SHARES
Basic Shares Outstanding	29.42M shares	29.23M shares	28.89M shares
Diluted Shares Outstanding			28.89M shares

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$120.7M	$107.8M	$160.5M
YoY Change	-18.61%	-32.83%	-22.69%
Cash & Equivalents	$120.7M	$107.8M	$160.5M
Short-Term Investments			$0.00
Other Short-Term Assets	$2.700M	$4.900M	$4.000M
YoY Change	-74.77%	22.5%	-64.6%
Inventory
Prepaid Expenses			$4.048M
Receivables
Other Receivables	$10.67M	$11.26M
Total Short-Term Assets	$134.2M	$130.2M	$172.0M
YoY Change	-25.1%	-24.29%	-26.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.527M	$5.886M	$7.435M
YoY Change	-23.11%	-20.83%	-15.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.527M	$5.886M	$7.435M
YoY Change	-23.11%	-20.83%	-15.49%
TOTAL ASSETS
Total Short-Term Assets	$134.2M	$130.2M	$172.0M
Total Long-Term Assets	$5.527M	$5.886M	$7.435M
Total Assets	$139.7M	$136.1M	$179.4M
YoY Change	-25.02%	-24.14%	-26.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.86M	$11.37M	$1.843M
YoY Change	401.06%	516.87%	25.03%
Accrued Expenses	$13.83M	$14.45M	$19.54M
YoY Change	-62.88%	-26.02%	228.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	-64.03%
Total Short-Term Liabilities	$26.09M	$26.30M	$22.55M
YoY Change	-35.81%	16.67%	149.5%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$200.0K	$400.0K
YoY Change	-66.67%	-50.0%	-11.11%
Other Long-Term Liabilities	$7.000M	$7.000M	$7.200M
YoY Change	-1.41%	-2.78%	-10.0%
Total Long-Term Liabilities	$7.159M	$7.218M	$7.560M
YoY Change	-3.54%	-4.52%	-10.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.09M	$26.30M	$22.55M
Total Long-Term Liabilities	$7.159M	$7.218M	$7.560M
Total Liabilities	$33.25M	$33.52M	$30.11M
YoY Change	-30.83%	11.35%	72.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$223.8M	-$203.1M	-$136.5M
YoY Change	47.22%	48.87%	278.72%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.113M	$1.098M	$784.0K
YoY Change	41.96%	40.05%	42.29%
Treasury Stock Shares	55.78K shares	53.43K shares	25.23K shares
Shareholders Equity	$106.5M	$102.6M	$149.3M
YoY Change
Total Liabilities & Shareholders Equity	$139.7M	$136.1M	$179.4M
YoY Change	-25.02%	-24.14%	-26.23%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$20.63M	-$16.73M	-$32.39M
YoY Change	32.73%	-48.36%	129.86%
Depreciation, Depletion And Amortization	$400.0K	$300.0K	$600.0K
YoY Change	33.33%	-50.0%	100.0%
Cash From Operating Activities	-$7.200M	-$10.90M	-$16.20M
YoY Change	-45.45%	-32.72%	153.13%
INVESTING ACTIVITIES
Capital Expenditures	$100.0K	-$100.0K	-$1.700M
YoY Change	-200.0%	-94.12%	13.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$200.0K	$1.000M
YoY Change		-80.0%	-72.22%
Cash From Investing Activities	$0.00	$100.0K	-$700.0K
YoY Change	-100.0%	-114.29%	-133.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00M	300.0K	400.0K
YoY Change	1718.18%	-25.0%	-63.64%
NET CHANGE
Cash From Operating Activities	-7.200M	-10.90M	-16.20M
Cash From Investing Activities	0.000	100.0K	-700.0K
Cash From Financing Activities	20.00M	300.0K	400.0K
Net Change In Cash	12.80M	-10.50M	-16.50M
YoY Change	-204.92%	-36.36%	415.63%
FREE CASH FLOW
Cash From Operating Activities	-$7.200M	-$10.90M	-$16.20M
Capital Expenditures	$100.0K	-$100.0K	-$1.700M
Free Cash Flow	-$7.300M	-$10.80M	-$14.50M
YoY Change	-44.27%	-25.52%	195.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29421041	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	159637289	USD
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2014	nlnk	Collaborative Arrangement Numberof Arrangements CollaborativeArrangementNumberofArrangements	2	arrangement
CY2016Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2017Q2	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2017Q2	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	2600000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22883000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11369000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14309000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14453000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5700000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6400000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	295535000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	306555000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10568000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9200000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4600000	USD
CY2016Q4	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	2900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10600000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3976000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q4	us-gaap	Assets Assets	174747000	USD
CY2017Q2	us-gaap	Assets Assets	136124000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	167912000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	130238000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	231000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195620000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160527000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131490000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107777000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-35093000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23713000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29193718	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29334727	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29163673	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29281301	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	292000	USD
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	293000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	92000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1091000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1045000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	391000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	167000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1204000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	707000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.94
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	127000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-113000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	397000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9130000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18294000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8897000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17131000	USD
CY2016Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	23900000	USD
CY2017Q2	us-gaap	Government Contract Receivable GovernmentContractReceivable	10700000	USD
CY2016Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4300000	USD
CY2017Q2	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	3400000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34468000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59822000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16726000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37949000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2079000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3713000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3700000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-310000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-310000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1022000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	5975000	USD
CY2017Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6287000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8958000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11356000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5118000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-312000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	55000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	44000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-405000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-224000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2208000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-13268000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-906000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1005000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	6000	USD
	us-gaap	Interest Expense InterestExpense	13000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	7000	USD
	us-gaap	Interest Expense InterestExpense	113000	USD
	us-gaap	Interest Paid InterestPaid	12000	USD
	us-gaap	Interest Paid InterestPaid	8000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	66000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	112000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	117000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	202000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	45281000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	33521000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174747000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136124000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37905000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	26303000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7376000	USD
CY2017Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7218000	USD
CY2017Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	843000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	750000	USD
	us-gaap	Licenses Revenue LicensesRevenue	2120000	USD
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue	56000	USD
	us-gaap	Licenses Revenue LicensesRevenue	231000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	285000	USD
CY2017Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	173000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	232000	USD
CY2017Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	222000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	517000	USD
CY2017Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	395000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	426000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	196000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	115000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35715000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23914000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-32389000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56109000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-16726000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37639000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	60000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	99000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24000	USD
	us-gaap	Notes Reduction NotesReduction	397000	USD
	us-gaap	Notes Reduction NotesReduction	0	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	36540000	USD
	us-gaap	Operating Expenses OperatingExpenses	67641000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	27097000	USD
	us-gaap	Operating Expenses OperatingExpenses	51056000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-34528000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59921000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16727000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37925000	USD
CY2016Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	109000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	113000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24526000	USD
CY2017Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	11258000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	245000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	42000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1984000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5921000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4916000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	575000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	453000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	2180000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	172000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6835000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5886000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	136000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	122000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27410000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49347000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18200000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33925000	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	11600000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	42000	USD
CY2017Q2	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165508000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203147000	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	1262000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	5600000	USD
CY2017Q2	us-gaap	Revenue From Grants RevenueFromGrants	10314000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	12900000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2012000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	7720000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	10370000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	13131000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9244000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10568000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	325000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	128000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	245000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	129466000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	102603000	USD
CY2016	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	4000000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	30045	shares
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	53426	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	853000	USD
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1098000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28891827	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28874385	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29225386	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29219469	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company’s Annual Report on Form 10-K. There were no significant changes in the Company’s accounting policies since the end of fiscal </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The financial results for any interim period are not necessarily indicative of financial results for the full year.</font></div></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$16.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from an at the market (ATM) offering completed in 2015. Additionally, on November 29, 2016, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. (Cantor) under which the Company may sell up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock in one or more placements at prevailing market prices in an ATM offering. The Company launched this ATM offering in June 2017. Subsequent to </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and through the date of this filing, </font><font style="font-family:inherit;font-size:10pt;">139,740</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were sold under this ATM, with aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> after commissions of </font><font style="font-family:inherit;font-size:10pt;">$22,000</font><font style="font-family:inherit;font-size:10pt;"> paid to Cantor as the placement agent. In connection with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements through 2018. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-17-000081-index-headers.html	Edgar Link	pending
0001126234-17-000081-index.html	Edgar Link	pending
0001126234-17-000081.txt	Edgar Link	pending
0001126234-17-000081-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
idopathwaychartv162.jpg	Edgar Link	pending
newlinklogorgbwtaga01a01a08.jpg	Edgar Link	pending
nlnk-20170630.xml	Edgar Link	completed
nlnk-20170630.xsd	Edgar Link	pending
nlnk-20170630x10q.htm	Edgar Link	pending
nlnk-20170630xex311.htm	Edgar Link	pending
nlnk-20170630xex312.htm	Edgar Link	pending
nlnk-20170630xex321.htm	Edgar Link	pending
nlnk-20170630_cal.xml	Edgar Link	unprocessable
nlnk-20170630_def.xml	Edgar Link	unprocessable
nlnk-20170630_lab.xml	Edgar Link	unprocessable
nlnk-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2017 Q3 Form 10-Q Financial Statement

#000112623417000081 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2017 Q3 Form 10-Q Financial Statement

#000112623417000081 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo